|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Inhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on infectious disease. |
|---|---|
| Transferring Party | FermaVir Pharmaceuticals, Inc. (OTC BB: FMVR), a company with an antiviral development-stage pipeline that includes a highly potent treatment for shingles. |
| Sector | Biopharmaceuticals |
| Date | April 10, 2007 |
| Analysis Inhibitx gets the shingles drug about to enter early-stage clinical trials, as well as a series of preclinical compounds to treat human cytomegalovirus, a member of the herpes virus group, which includes viruses that cause chicken pox, mononucleosis and herpes simplexes 1 and 2. Deal value - $19m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |